UNH's troubles are piling up, from a fresh DOJ criminal probe and rising costs to leadership shakeups and pulled guidance.

Humana has a P/E ratio of 16.4 based on its 12 month trailing earnings per share of $14.17. Considering its future earnings ...

"The company suspended its 2025 outlook as care activity continued to accelerate while also broadening to more types of benefit offerings than seen in the first quarter, and the medical costs of many ...

Shares of Humana Inc. HUM shed 1.51% to $249.53 Friday, on what proved to be an all-around grim trading session for the stock ...

UnitedHealth Group Incorporated's stock faces a steep decline amid leadership turmoil, regulatory pressures, and rising costs ...

Can prescription benefit managers, or PBMs, be eliminated from the U.S. drug pricing process? Seeking Alpha analysts weigh in. Read more here.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

The latest price target for Humana (NYSE:HUM) was reported by Truist Securities on May 12, 2025. The analyst firm set a price target for $305.00 expecting HUM to rise to within 12 months (a ...

India-Pakistan tensions: Following the Pahalgam terror attack and Operation Sindoor, India's stock market has shown resilience with minimal decline, contrasting ...

"Dr. Karp's participation in the official visit to Saudi Arabia, combined with the inclusion of Saudi Arabia and other gulf states in the US' AI initiatives may open a new market for Palantir," DA ...

Health insurer Humana has filed a lawsuit against telemedicine company QuivvyTech that it says resulted in fraudulent prescriptions worth millions of dollars being written for duped customers.